Literature DB >> 16920977

Active participation of antigen-nonspecific lymphoid cells in immune-mediated inflammation.

Jun Chen1, Chiaki Fujimoto, Barbara P Vistica, JianPing He, Eric F Wawrousek, Brian Kelsall, Igal Gery.   

Abstract

The pathogenic process of tissue-specific autoimmune disease depends to a large extent on recruitment of Ag-nonspecific cells into the target tissue. Little is known, however, about the recruitment process and the features that characterize the recruited cells. In this study, we analyzed the recruitment of Ag-nonspecific lymphoid cells into an inflammatory site by using an experimental system in which TCR-transgenic Th1 cells are adoptively transferred to induce ocular inflammation in recipient mice that express the target Ag in their eyes. A sharp increase in number of all host cell populations was observed in the recipient spleen, reaching a peak on day 4 postcell transfer and declining thereafter. A large portion of the host's spleen CD4 cells underwent phenotypic changes that facilitate their migration into the target organ, the eye. These changes included increased expression of the chemokine receptor CXCR3, and the adhesion molecule CD49d, as well as a decline in expression of CD62L. The host lymphocytes migrated into the recipient mouse eye more slowly than the donor cells, but became the great majority of the infiltrating cells at the peak of inflammation on day 7 postcell injection. Interestingly, the mass migration of host T cells was preceded by an influx of host dendritic cells, that reached their peak on day 4 postcell injection. The eye-infiltrating host CD4 lymphocytes underwent additional changes, acquiring a profile of activated lymphocytes, i.e., up-regulation of CD25 and CD69. Our results thus provide new information about the active participation of Ag-nonspecific lymphoid cells in immune-mediated inflammation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16920977     DOI: 10.4049/jimmunol.177.5.3362

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Phenotype switching by inflammation-inducing polarized Th17 cells, but not by Th1 cells.

Authors:  Guangpu Shi; Catherine A Cox; Barbara P Vistica; Cuiyan Tan; Eric F Wawrousek; Igal Gery
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

2.  In situ recognition of autoantigen as an essential gatekeeper in autoimmune CD8+ T cell inflammation.

Authors:  Jinguo Wang; Sue Tsai; Afshin Shameli; Jun Yamanouchi; Gonnie Alkemade; Pere Santamaria
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-03       Impact factor: 11.205

3.  Type I Interferon Therapy Limits CNS Autoimmunity by Inhibiting CXCR3-Mediated Trafficking of Pathogenic Effector T Cells.

Authors:  Weiwei Wang; Wai Po Chong; Chunmei Li; Zilin Chen; Sihan Wu; Hongyan Zhou; Ying Wan; Wanjun Chen; Igal Gery; Yizhi Liu; Rachel R Caspi; Jun Chen
Journal:  Cell Rep       Date:  2019-07-09       Impact factor: 9.423

4.  Phenotypes of Th lineages generated by the commonly used activation with anti-CD3/CD28 antibodies differ from those generated by the physiological activation with the specific antigen.

Authors:  Cuiyan Tan; Lai Wei; Barbara P Vistica; Guangpu Shi; Eric F Wawrousek; Igal Gery
Journal:  Cell Mol Immunol       Date:  2014-03-03       Impact factor: 11.530

5.  Microbial products trigger autoimmune ocular inflammation.

Authors:  Chiaki Fujimoto; Guangpu Shi; Igal Gery
Journal:  Ophthalmic Res       Date:  2008-04-18       Impact factor: 2.892

6.  Unlike Th1, Th17 cells mediate sustained autoimmune inflammation and are highly resistant to restimulation-induced cell death.

Authors:  Guangpu Shi; Madhu Ramaswamy; Barbara P Vistica; Catherine A Cox; Cuiyan Tan; Eric F Wawrousek; Richard M Siegel; Igal Gery
Journal:  J Immunol       Date:  2009-11-04       Impact factor: 5.422

7.  Both Th1 and Th17 are immunopathogenic but differ in other key biological activities.

Authors:  Catherine A Cox; Guangpu Shi; Hongen Yin; Barbara P Vistica; Eric F Wawrousek; Chi-Chao Chan; Igal Gery
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.